Can a decision-making model be justified in the management of hepatocellular adenoma?

Liver International

Volumn 32, Issue 1, 2012, Pages 28-37

  van Aalten, Susanna M ^a   Witjes, Caroline D M ^a   de Man, Robert A ^a   Ijzermans, Jan N M ^a   Terkivatan, Türkan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Liver adenoma; Management; Treatment

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID; ORAL CONTRACEPTIVE AGENT; SONOVUE; SUPERPARAMAGNETIC IRON OXIDE;

ARTIFICIAL EMBOLISM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG UPTAKE; DRUG WITHDRAWAL; HEPATOCELLULAR ADENOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INCIDENCE; LIVER ADENOMA; LIVER BIOPSY; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW; TUMOR BLEEDING;

ADENOMA, LIVER CELL; CELL TRANSFORMATION, NEOPLASTIC; DECISION MAKING; DECISION THEORY; FEMALE; HEMORRHAGE; HUMANS; LIVER NEOPLASMS; MALE; MODELS, THEORETICAL; OPERATIONS RESEARCH; PROGNOSIS;

EID: 83255193973     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02667.x     Document Type: Review

References (81)

1. Reddy KR, Schiff ER. Approach to a liver mass. Semin Liver Dis 1993; 13: 423-35.
2. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242: 644-8.
3. Giannitrapani L, Soresi M, La Spada E, et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006; 1089: 228-36.
4. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985; 89: 1132-8.
5. Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21: 877-92.; discussion 92-4.
6. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-77.
7. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46: 740-8.
8. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50: 481-9.
9. Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C. Hepatocellular adenoma: what is new in 2008. Hepatol Int 2008; 2: 316-21.
10. Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003; 125: 1470-5.
11. Paradis V, Champault A, Ronot M, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007; 46: 140-6.
12. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43: 515-24.
13. Van Aalten SM, Verheij J, Terkivatan T, et al. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol 2011; 55: 120-5.
14. Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis 2011; 31: 91-103.
15. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005; 128: 1211-8.
16. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004; 126: 1323-9.
17. Yan BC, Hart JA. Recent developments in liver pathology. Arch Pathol Lab Med 2009; 133: 1078-86.
18. Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988; 208: 558-64.
19. Hussain SM, Van Den Bos IC, Dwarkasing RS, Kuiper JW, Den Hollander J. Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. Eur Radiol 2006; 16: 1873-86.
20. Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009; 16: 640-8.
21. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137: 1698-705.
22. Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 2004; 187: 181-91.
23. Erdogan D, Busch OR, Van Delden OM, et al. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. Liver Int 2006; 26: 433-8.
24. Huurman VA, Schaapherdera F. Management of ruptured hepatocellular adenoma. Dig Surg 2010; 27: 56-60.
25. Micchelli ST, Vivekanandan P, Boitnott JK, et al. Malignant transformation of hepatic adenomas. Mod Pathol 2008; 21: 491-7.
26. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994; 129: 712-7.
27. Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol 2008; 15: 2795-803.
28. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12: 509-22.
29. Cassiman D, Libbrecht L, Verslype C, et al. An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild Glycogen Storage Disease type Ia. J Hepatol 2010; 53: 213-7.
30. Franco LM, Krishnamurthy V, Bali D, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 2005; 28: 153-62.
31. Kishnani PS, Chuang TP, Bali D, et al. Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. Hum Mol Genet 2009; 18: 4781-90.
32. Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994; 120: 218-26.
33. Van Aalten SM, Verheij J, Terkivatan T, et al. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol 2011; 55: 120-5.
34. Terkivatan T, De Wilt JH, De Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001; 136: 1033-8.
35. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002; 32: 312-5.
36. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457: 200-4.
37. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008; 48: 163-70.
38. Ronot M, Bahrami S, Calderaro J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011; 53: 1182-91.
39. Terkivatan T, Hussain SM, De Man RA, Ijzermans JN. Diagnosis and treatment of benign focal liver lesions. Scand J Gastroenterol Suppl 2006; 243: 102-15.
40. Denys A, Arrive L, Servois V, et al. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology 1994; 193: 665-9.
41. Vogl TJ, Hammerstingl R, Schwarz W, et al. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest Radiol 1996; 31: 696-708.
42. Beets-Tan RG, Van Engelshoven JM, Greve JW. Hepatic adenoma and focal nodular hyperplasia: MR findings with superparamagnetic iron oxide-enhanced MRI. Clin Imaging 1998; 22: 211-5.
43. Paley MR, Mergo PJ, Torres GM, Ros PR. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol 2000; 175: 159-63.
44. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-78.
45. Giovanoli O, Heim M, Terracciano L, Bongartz G, Ledermann HP. MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients. AJR Am J Roentgenol 2008; 190: W290-3.
46. Van Den Bos IC, Hussain SM, De Man RA, et al. Primary hepatocellular lesions: imaging findings on state-of-the-art magnetic resonance imaging, with pathologic correlation. Curr Probl Diagn Radiol 2008; 37: 104-14.
47. Grazioli L, Bondioni MP, Faccioli N, et al. Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine. J Gastrointest Cancer 2010; 41: 221-32.
48. Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Focal liver lesions: contrast-enhanced ultrasound. Abdom Imaging 2009; 34: 193-209.
49. Kim TK, Jang HJ, Burns PN, Murphy-Lavallee J, Wilson SR. Focal nodular hyperplasia and hepatic adenoma: differentiation with low-mechanical-index contrast-enhanced sonography. AJR Am J Roentgenol 2008; 190: 58-66.
50. Van Den Esschert JW, Van Gulik TM, Phoa SS. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Dig Surg 2010; 27: 46-55.
51. Piscaglia F, Lencioni R, Sagrini E, et al. Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol 2010; 36: 531-50.
52. Dietrich CF, Schuessler G, Trojan J, Fellbaum C, Ignee A. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78: 704-7.
53. Soussan M, Aube C, Bahrami S, et al. Incidental focal solid liver lesions: diagnostic performance of contrast-enhanced ultrasound and MR imaging. Eur Radiol 2010; 20: 1715-25.
54. Romanini L, Passamonti M, Aiani L, et al. Economic assessment of contrast-enhanced ultrasonography for evaluation of focal liver lesions: a multicentre Italian experience. Eur Radiol 2007; 17(Suppl 6): F99-106.
55. Van Den Esschert JW, Bieze M, Beuers UH, Van Gulik TM, Bennink RJ. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using (18) F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging 2011; 38: 436-40.
56. Laumonier H, Bioulac-Sage P, Laurent C, et al. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008; 48: 808-18.
57. Van Aalten SM, Thomeer MGJ, Terkivatan T, et al. Hepatocellular adenomas: Correlation of MR imaging findings with pathological subtype classification. Radiology 2011; 261: 172-81.
58. Aseni P, Sansalone CV, Sammartino C, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 2001; 33: 234-6.
59. Van Aalten SM, Terkivatan T, De Man RA, et al. Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences. Dig Surg 2010; 27: 61-7.
60. Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC. Selective management of hepatic adenomas. Am Surg 1996; 62: 825-9.
61. Terkivatan T, De Wilt JH, De Man RA, et al. Treatment of ruptured hepatocellular adenoma. Br J Surg 2001; 88: 207-9.
62. Van Der Windt DJ, Kok NF, Hussain SM, et al. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006; 93: 1495-502.
63. Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011; 60: 85-9.
64. Atwell TD, Brandhagen DJ, Charboneau JW, et al. Successful treatment of hepatocellular adenoma with percutaneous radiofrequency ablation. AJR Am J Roentgenol 2005; 184: 828-31.
65. Fujita S, Kushihata F, Herrmann GE, et al. Combined hepatic resection and radiofrequency ablation for multiple hepatic adenomas. J Gastroenterol Hepatol 2006; 21: 1351-4.
66. Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular adenoma: initial experience in 10 patients. J Gastroenterol Hepatol 2008; 23: e422-7.
67. Van Der Sluis FJ, Bosch JL, Terkivatan T, et al. Hepatocellular adenoma: cost-effectiveness of different treatment strategies. Radiology 2009; 252: 737-46.
68. Buscarini L, Rossi S, Fornari F, Di Stasi M, Buscarini E. Laparoscopic ablation of liver adenoma by radiofrequency electrocauthery. Gastrointest Endosc 1995; 41: 68-70.
69. Rocourt DV, Shiels WE, Hammond S, Besner GE. Contemporary management of benign hepatic adenoma using percutaneous radiofrequency ablation. J Pediatr Surg 2006; 41: 1149-52.
70. Erdogan D, Van Delden OM, Busch OR, Gouma DJ, Van Gulik TM. Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc Intervent Radiol 2007; 30: 1252-8.
71. Stoot JH, Van Roosmalen J, Terpstra OT, Schaapherder F. Life-threatening hemorrhage from adenomas in the liver during pregnancy. Dig Surg 2006; 23: 155.
72. Huurman VA, Stoot JH, Van Der Linden E, Terpstra OT, Schaapherdera F. Necrosis of a large hepatic tumor after hemorrhage and subsequent selective arterial embolization. World J Gastroenterol 2006; 12: 6059-61.
73. Noels JE, Van Aalten SM, Van Der Windt DJ, et al. Management of hepatocellular adenoma during pregnancy. J Hepatol 2011; 54: 553-8.
74. Chiche L, Dao T, Salame E, et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg 2000; 231: 74-81.
75. Vetelainen R, Erdogan D, De Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 2008; 28: 499-508.
76. Babaoglu K, Binnetoglu FK, Aydogan A, et al. Hepatic adenomatosis in a 7-year-old child treated earlier with a Fontan procedure. Pediatr Cardiol 2010; 31: 861-4.
77. Brunt EM, Wolverson MK, Di Bisceglie a M. Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. Semin Liver Dis 2005; 25: 230-6.
78. Furlan A, Van Der Windt DJ, Nalesnik MA, et al. Multiple hepatic adenomas associated with liver steatosis at CT and MRI: a case-control study. AJR Am J Roentgenol 2008; 191: 1430-5.
79. Kobayashi S, Sakaguchi H, Takatsuka M, et al. Two cases of hepatocellular adenomatosis treated with transcatheter arterial embolization. Hepatol Int 2009; 3: 416-20.
80. Di Sandro S, Slim A O, Lauterio A, et al. Liver adenomatosis: a rare indication for living donor liver transplantation. Transplant Proc 2009; 41: 1375-7.
81. Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 2005; 7: 186-96.